Senado, “Proyecto de Ley: Modifica El Código Sanitario Para Regular Los Medicamentos Bioequivalentes Genéricos y Evitar La Integración Vertical de Laboratorios y Farmacias,” 2015, available at <https://www.senado.cl/appsenado/templates/tramitacion/index.php?boletin_ini=9914-11> (last visited July 26, 2023); “Proyecto de Ley 5311,” 2020, available at <https://leyes.congreso.gob.pe/Documentos/2016_2021/Proyectos_de_Ley_y_de_Resoluciones_Legislativas/PL05311-20200521.pdf> (last visited July 26, 2023); Decreto supremo N° 4452, “Estado Plurinacional de Bolivia,” 2020, available at <https://www.agemed.gob.bo/resoluciones/DS_4452_2021.pdf> (last visited July 26, 2023).+(last+visited+July+26,+2023);+“Proyecto+de+Ley+5311,”+2020,+available+at++(last+visited+July+26,+2023);+Decreto+supremo+N°+4452,+“Estado+Plurinacional+de+Bolivia,”+2020,+available+at++(last+visited+July+26,+2023).>Google Scholar

WHA72.8 - Improving the Transparency of Markets for Medicines, Vaccines, and Other Health Products,” n.d. World Health Assembly, available at <https://www.who.int/publications/m/item/wha72.8> (last visited July 26, 2023).+(last+visited+July+26,+2023).>Google Scholar

Gilardino, R.E., Valanzasca, P., and Rifkin, S.B., “Has Latin America Achieved Universal Health Coverage Yet? Lessons from Four Countries,” Archives of Public Health = Archives Belges de Sante Publique 80, no. 1 (2022).Google ScholarPubMed

Wagstaff, A., Eozenou, P., and Smitz, M., “Out-of-Pocket Expenditures on Health: A Global Stocktake,” The World Bank Research Observer 35, 1no. 2 (2022): 123–57; C. Cid, G. Flores, A. Del Riego, and J. Fitzgerald, “[Sustainable Development Goals: Impact of Lack of Financial Protection in Health in Latin American and Caribbean CountriesObjetivos de Desenvolvimento Sustentável: Impacto Da Falta de Proteção Financeira Em Saúde Nos Países Da América Latina e Do Caribe],” Revista Panamericana de Salud Publica = Pan American Journal of Public Health 45 (2021).CrossRefGoogle Scholar

Tobar, F. and Martich, E., “Economic Tools for Ensuring Access to Medicines in Latin American Countries,” Pharmaceuticals Policy and Law 16, nos. 3–4 (2014): 207–224.CrossRefGoogle Scholar

Moye-Holz, D. and Vogler, S., “Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America,” Applied Health Economics and Health Policy 20, no. 1 (2022): 67–77.CrossRefGoogle ScholarPubMed

“WHO Guideline on Country Pharmaceutical Pricing Policies,” WHO, 2020, available at <https://www.who.int/publications/i/item/9789240011878> (last visited July 26, 2023).+(last+visited+July+26,+2023).>Google Scholar

S. Vogler, “Payer Policies to Support Innovation and Access to Medicines in the WHO European Region,” Copenhagen, 2022, available at <https://www.who.int/europe/publications/i/item/9789289058247> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

“PPRI Indicators,” Vienna, available at <https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/List_PPRI_Indicators_1.pdf> (last visited July 26, 2023.+(last+visited+July+26,+2023.>Google Scholar

Vogler, S., Leopold, C., Zimmermann, N., Habl, C., and de Joncheere, K., “The Pharmaceutical Pricing and Reimbursement Information (PPRI) Initiative-Experiences from Engaging with Pharmaceutical Policy Makers,” Health Policy and Technology 3, no. 2 (2014); S. Vogler and N. Zimmermann, “Improving Medicines Access in Brazil through Collaboration in the PPRI Network,” Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 13, no. 2 (2022): 677–677.CrossRefGoogle Scholar

Balbino, J. Espin, Forns, J. Rovira, and González, C. Vaca, “Chapter 2.4 - Medicine Prices in Latin American Countries,” Medicine Price Surveys, Analyses and Comparisons 61–83 (2019).CrossRefGoogle Scholar

Moye-Holz and Vogler, supra note 6.Google Scholar

Estay, Martínez and Bugueño, R.A. Poyanco, “El Derecho a La Vida En La Jurisprudencia de La Corte Suprema Sobre Medicamentos de Alto Costo,” Estudios Constitucionales 20, no. 2 (2022): 2–40; T.S. Andia and E. Lamprea, “Is the Judicialization of Health Care Bad for Equity? A Scoping Review,” International Journal for Equity in Health 18, no. 1 (2019).Google Scholar

Yamin, A.E., Andrés Pichon-Riviere, A., and Bergallo, P., “Unique Challenges for Health Equity in Latin America: Situating the Roles of Priority-Setting and Judicial Enforcement,” International Journal for Equity in Health 18, no. 1 (2019).CrossRefGoogle ScholarPubMed

Vargas-Pelaez, C.M., Rover, M. Raijche Mattozo, Soares, L., Blatt, C. Raquel, Mantel-Teeuwisse, A.K., Rossi, Francisco Augusto, Restrepo, Luis Guillermo, et al., “Judicialization of Access to Medicines in Four Latin American Countries: A Comparative Qualitative Analysis.” International Journal for Equity in Health 18, no. 1 (2019); L.A. Salha, Leila, F. Costa Reis, R. Moreira Gonçalves, J. Horácio da Silva Lima, N. Abou Salha, R. Pereira Pinto, J. Elmo de Menezes, E. Perez Oliveira, P. Lopes Ferreira, and M. Alves Barbosa, “Judicialization of Health: Profile of Demands for Oncological Medicines in a State in the Central Region of Brazil,” International Journal for Equity in Health 21, no. 1 (2022).CrossRefGoogle ScholarPubMed

Andia and Lamprea, supra note 13; Freiberg, A. and Espin, J., “Towards a Taxonomy of Judicialisation for Access to Medicines in Latin America,” Global Public Health 17, no. 6 (2022): 912–25.CrossRefGoogle ScholarPubMed

Id. Google Scholar

Pinzón-Flórez, C.E., Chapman, E., Cubillos, L., and Reveiz, L., “Priorización de Estrategias Para El Abordaje de La Judicialización En Salud En América Latina y El Caribe,” Revista de Saude Publica 50 (2016); Vargas-Pelaez et al., supra note 15; A. Acosta, M.Z. Falcão, F.M.A. Aith, and C. Vance, “Judicialización Del Acceso a Medicamentos En El Contexto Suramericano,” Revista De Direito Sanitário (2019), available at <https://www.saludyfarmacos.org/lang/es/boletin-farmacos/boletines/feb202002/05_ju/> (last visited July 27, 2023).Google Scholar

Floriano, F.R., Raynal, F., Boeira, L., de Agostino Biella, C., Pereira, V. Cássia, Carvalho, M., Barreto, J. Otávio Maia, and do Valle Leone de Oliveira, S. Maria, “Strategies to Approach the Judicialization of Health in Brazil: An Evidence Brief,” Ciencia & Saude Coletiva 28, no. 1 (2023): 181–96; Martínez Estay and Poyanco Bugueño, supra note 13; Freiberg and Espin, supra note 16.Google ScholarPubMed

Luiza, V.L., Oliveira, M. Auxiliadora, Chaves, G. Costa, Flynn, M.B., and Bermudez, J.A. Zepeda, “Pharmaceutical Policy in Brazil,” Pharmaceutical Policy in Countries with Developing Healthcare Systems (January 2017): 123–49.CrossRefGoogle ScholarPubMed

Ivama-Brummell, A.M., Marciniuk, F.L., Wagner, A.K., Osorio-de-Castro, C.G.S., Vogler, S., Mossialos, E., Tavares-de-Andrade, C.L., and Naci, H., “Marketing Authorisation and Pricing of FDA-Approved Cancer Drugs in Brazil: A Retrospective Analysis,” Lancet Regional Health - Americas 22 (June 2023): 100506; A.M. Ivama-Brummell, D. Pingret-Kipman, P.G. Louly, and R.R. Andrade, “Medicines Regulation, Pricing and Reimbursement in Brazil,” Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 13, no. 1 (2022): 769-769.CrossRefGoogle Scholar

Luiza, et al., supra note 20.Google Scholar

Banco Interamericano de Desarrollo, “Acceso, desarrollo y regulación económica del mercado de medicamentos de Brasil,” 2022, Breve 25, avalaible at <https://publications.iadb.org/es/breve-25-acceso-desarrollo-y-regulacion-economica-del-mercado-de-medicamentos-de-brasil> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

Ivama-Brummell, et al., supra note 21.Google Scholar

Id. Google Scholar

T. Andia, “El ‘Efecto Portafolio’ de La Regulación de Precios de Medicamentos: La Respuesta de La Industria Farmacéutica a La Regulación de Precios de Medicamentos En Colombia,” September 2018.CrossRefGoogle Scholar

Prada, S.I., Soto, V.E., Andia, T.S., Vaca, C.P., Morales, Á.A., Márquez, S.R., and Gaviria, A., “Higher Pharmaceutical Public Expenditure after Direct Price Control: Improved Access or Induced Demand? The Colombian Case,” Cost Effectiveness and Resource Allocation: C/E 16, no. 1 (2018).CrossRefGoogle ScholarPubMed

Id. Google Scholar

Andia, T., Gaviria, A., Gomez, C., Jaramillo, L.F., Marquez, S., Rodríguez, I., and Vaca, C., “First Evaluation Of Colombian’s External Reference Pricing System,” Value in Health 17, no. 3 (2014): A15.CrossRefGoogle Scholar

Dirección de Medicamentos y Tecnologías En Salud, Boletín Gasto de Bolsillo en Medicamentos, 2022.Google Scholar

Prada, et al., supra note 27.Google Scholar

Andia, supra note 26.Google Scholar

Dirección de Medicamentos y Tecnologías en Salud, supra note 30.Google Scholar

Durán, C.E., Lucio, R., and Rovira, J., “Pharmaceutical Policy in Ecuador,” Pharmaceutical Policy in Countries with Developing Healthcare Systems (2017): 221–236.CrossRefGoogle Scholar

Id.Google Scholar

“Cuadro Nacional de Medicamentos Básico CNMB – Ministerio de Salud Pública,” n.d., available at <https://www.salud.gob.ec/cuadro-nacional-de-medicamentos-basico-cnmb/> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

L. Rivera, “The Pharmaceutical Price Regulation in El Salvador,” 2022, available at <https://publications.iadb.org/en/breve-24-pharmaceutical-price-regulation-el-salvador> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

Id. Google Scholar

Hamilton, G. and Tobar, F., “Experiencias internacionales en la regulación del precio de los medicamentos,” in Lifschitz, E., Esteban, ed., Agencia de Evaluación de Tecnologías Sanitarias en Argentina: Por qué, Para qué y cómo (Buenos Aires: Fundación Sanatorio Guemes, 2018); Rivera, supra note 37.Google Scholar

E. González-Pier and M. Barraza-Lloréns, “Trabajando Por La Salud de La Población: Propuestas de Política Para El Sector Farmacéutico,” Mexico, 2011, available at <https://funsalud.org.mx/wp-content/uploads/2019/11/Doc-PolPublSFarm-vFDigital-060511.pdf> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

Cid, et al., supra note 4.Google Scholar

Moye-Holz and Vogler, supra note 6; F. Bañuelos F. 2016. “Mexico’s Coordinating Commission for Negotiating the Price of Medicines and Other Health Inputs,” available at <https://publications.iadb.org/en/breve-14-mexicos-coordinating-commission-negotiating-price-medicines-and-other-health-inputs> (last visited July 28, 2023); Gómez-Dantés, O., Wirtz, V.J., Reich, M.R., Terrazas, P., and Ortiz, M., “A New Entity for the Negotiation of Public Procurement Prices for Patented Medicines in Mexico.” Bulletin of the World Health Organization 90, no. 10 (2012): 788.CrossRefGoogle ScholarPubMed

Moye-Holz and Vogler, supra note 6.Google Scholar

Poblete, S., “Precio Máximo Industrial: Instrumento Para La Negociación y La Regulación de Los Precios de Medicamentos de Alto Costo En Chile,” Revista Chilena de Salud Pública 26, no. 1 (2022): 67–77.Google Scholar

“Ley 20850 Crea Un Sistema de Protección Financiera Para Diagnósticos y Tratamientos de Alto Costo,” n.d. Ministerio de Salud, available at <https://www.bcn.cl/leychile/navegar?idNorma=1078148> (last visited July 28, 2023); Id. (Poblete).+(last+visited+July+28,+2023);+Id.+(Poblete).>Google Scholar

S. Vogler, M.A. Haasis, G. Dedet, J. Lam, and H. Bak Pedersen, “Medicines Reimbursement Policies in Europe,” Copenhagen, 2018, available at <https://www.who.int/europe/publications/i/item/9789289053365> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

Vogler, S., Dedet, G., and Pedersen, H. Bak, “Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries,” Applied Health Economics and Health Policy 17, no. 6 (2019): 803–816.Google ScholarPubMed

S. Vogler, N. Zimmermann, and M.A. Haasis, “PPRI Report 2018 - Pharmaceutical Pricing and Reimbursement Policies in 47 PPRI Network Member Countries,” WHO Collaborating Centre for Pricing and Reimbursement Policies, 2019, available at <https://jasmin.goeg.at/1068/> (last visited October 18, 2023) .+(last+visited+October+18,+2023)+.>Google Scholar

Vogler, S., Haasis, M.A., van den Ham, R., Humbert, T., Garner, S., and Suleman, F., “European Collaborations on Medicine and Vaccine Procurement,” Bulletin of the World Health Organization 99, no. 10 (2021): 715–21, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477421/pdf/BLT.21.285761.pdf> (last visited July 28, 2023); S. Vogler, M. Salcher-Konrad, and K. Habimana, “Study on Best Practices in the Public Procurement of Medicines: Final Report,” Brussels, 2022, available at <https://data.europa.eu/doi/10.2925/044781> (last visited July 28, 2023); S. Vogler, M.A. Haasis, R. van den Ham, F. Suleman, T. Humbert, and S. Garner, “Cross-Country Collaborations to Improve Access to Medicines and Vaccines in the WHO European Region,” Copenhagen, 2020, available at <https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Cross-country%20collaborations_final.pdf> (last visited July 28, 2023).CrossRefGoogle Scholar

Leopold, C., Vogler, S., Mantel-Teeuwisse, A.K., de Joncheere, K., Leufkens, H. G.M., and Laing, R., “Differences in External Price Referencing in Europe: A Descriptive Overview,” Health Policy (Amsterdam, Netherlands) 104, no. 1 (2012): 50–60; S. Vogler and P. Schneider, “Assessing Data Sources for Medicine Price Studies,” International Journal of Technology Assessment in Health Care 35, no. 2 (2019): 106-15.CrossRefGoogle ScholarPubMed

S. Vogler, L. Lepuschütz, P. Schneider, and and V. Stühlinger, “Study on Enhanced Cross-Country Coordination in the Area of Pharmaceutical Product Pricing - Publications Office of the EU,” Publications Office of the European Union, 2016, available at <https://op.europa.eu/en/publication-detail/-/publication/b1565784-9a9c-11e6-9bca-01aa75ed71a1/language-en> (last visited July 28, 2023); S. Vogler, N. Zimmermann, and M.A. Haasis, “PPRI Report 2018 - Pharmaceutical Pricing and Reimbursement Policies in 47 PPRI Network Member Countries,” WHO Collaborating Centre for Pricing and Reimbursement Policies, 2019, available at <https://jasmin.goeg.at/1068/> (last visited July 28, 2023).+(last+visited+July+28,+2023);+S.+Vogler,+N.+Zimmermann,+and+M.A.+Haasis,+“PPRI+Report+2018+-+Pharmaceutical+Pricing+and+Reimbursement+Policies+in+47+PPRI+Network+Member+Countries,”+WHO+Collaborating+Centre+for+Pricing+and+Reimbursement+Policies,+2019,+available+at++(last+visited+July+28,+2023).>Google Scholar

Vogler, S., Schneider, P., and Lepuschütz, L., “Impact of Changes in the Methodology of External Price Referencing on Medicine Prices: Discrete-Event Simulation,” Cost Effectiveness and Resource Allocation: C/E 18, no. 1 (2020); M. Toumi, C. Rémuzat, A.-L. Vataire, and D. Urbinati, “External Reference Pricing of Medicinal Products: Simulation-Based Considerations for Cross-Country Coordination Final Report Written by European Commission External Reference Pricing of Medicinal Products: Simulation-Based Considerations for Cross-Country Coordination 2/113 European Commission External Reference Pricing of Medicinal Products: Simulation-Based Considerations for Cross-Country Coordination,” 2013.CrossRefGoogle ScholarPubMed

Vogler and Schneider, supra note 50.Google Scholar

Vogler, et al., supra note 51.Google Scholar

E. Webb, E. Richardson, S. Vogler, and D. Panteli, “What Are the Implications of Policies Increasing Transparency of Prices Paid for Pharmaceuticals?” Copenhagen, 2022, available at <https://eurohealthobservatory.who.int/publications/i/what-are-the-implications-of-policies-increasing-transparency-of-prices-paid-for-pharmaceuticals#:~:text=Increasing%20transparency%20in%20the%20pharmaceutical,maintaining%20access%2C%20innovation%20and%20sustainability> (last visited July 28, 2023); Vogler, S., Schneider, P., and Zimmermann, N., “Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing,” PharmacoEconomics - Open 3, no. 3 (2019): 303–309; M.K. Kyle, “Pharmaceutical Price Controls and Entry Strategies,” The Review of Economics and Statistics 89, no. 1 (2007): 88-99.Google ScholarPubMed

Id. (Kyle).Google Scholar

Vogler, supra note 8.Google Scholar

S. Vogler, M.A. Haasis, and N. Zimmermann, “Brief Pharma Report Austria,” Vienna, 2019, available at <https://ppri.goeg.at/Brief_AT> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

S. Vogler, “International Comparison of Medicine Prices,” Medicine Price Surveys, Analyses and Comparisons: Evidence and Methodology Guidance (January 9-10, 2018).Google Scholar

EU-Durchschnittspreise Laut ASVG, Vienna: BMSGPK, 2022, available at <https://www.sozialministerium.at/Themen/Gesundheit/Medizin-und-Gesundheitsberufe/Medizin/Arzneimittel/Arzneimittelpreise/EU-Durchschnittspreise-laut-ASVG.html>..>Google Scholar

Id. Google Scholar

Id. Google Scholar

V. Paris and A. Belloni, “Value in Pharmaceutical Pricing: OECD Health Working Papers,” OECD, 2013, available at <https://www.oecd-ilibrary.org/social-issues-migration-health/value-in-pharmaceutical-pricing_5k43jc9v6knx-en> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

Vogler, et al., supra note 51; O’Rourke, B., Oortwijn, W., and Schuller, T., “The New Definition of Health Technology Assessment: A Milestone in International Collaboration,” International Journal of Technology Assessment in Health Care 36, no. 3 (2020): 187–90; A. Angelis, A. Lange, and P. Kanavos, “Using Health Technology Assessment to Assess the Value of New Medicines: Results of a Systematic Review and Expert Consultation across Eight European Countries,” The European Journal of Health Economics: HEPAC : Health Economics in Prevention and Care 19, no. 1 (2018): 123-52.CrossRefGoogle ScholarPubMed

S. Vogler, et al., “Medicines Reimbursement Policies in Europe,” WHO Europe, Copenhagen, 2018, available at <https://apps.who.int/iris/handle/10665/342220> (last visited July 28, 2023); Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on Health Technology Assessment and Amending Directive 2011/24/EU, 2021, Brussels: European Parliament and of the Council, available at <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R2282> (last visited July 28, 2023).+(last+visited+July+28,+2023);+Regulation+(EU)+2021/2282+of+the+European+Parliament+and+of+the+Council+of+15+December+2021+on+Health+Technology+Assessment+and+Amending+Directive+2011/24/EU,+2021,+Brussels:+European+Parliament+and+of+the+Council,+available+at++(last+visited+July+28,+2023).>Google Scholar

Vogler, S., Medicines Pricing: Limitations of Existing Policies and New Models (Singapore: Palgrave Macmillan, 2020).Google Scholar

See supra note 65.Google Scholar

Id. Google Scholar

O’Callaghan, J., Barry, S.P., Bermingham, M., Morris, J.M., and Griffin, B.T., “Regulation of Biosimilar Medicines and Current Perspectives on Interchangeability and Policy,” European Journal of Clinical Pharmacology 75, no. 1 (2019): 1–11.CrossRefGoogle ScholarPubMed

WHO Guideline, supra note 7.Google Scholar

W. Kaplan, V. Wirtz, and R. Laing, “Policy Options for Promoting the Use of Generic Medicines in Low-and Middle-Income Countries” 2016; Ferrario, A., Dedet, G., Humbert, T., Vogler, S., Suleman, F., and Pedersen, H. Bak, “Strategies to Achieve Fairer Prices for Generic and Biosimilar Medicines,” BMJ 368 (January 2010).Google Scholar

Acosta, A., Ciapponi, A., Aaserud, M, Vietto, V., Austvoll-Dahlgren, A., Kösters, J.P., Vacca, C., Machado, M., Ayala, D. Hazbeydy Diaz, and Oxman, A.D., “Pharmaceutical Policies: Effects of Reference Pricing, Other Pricing, and Purchasing Policies,” The Cochrane Database of Systematic Reviews 2014, no. 10 (2014).Google ScholarPubMed

Vogler, S., Panteli, D., Zimmermann, N., and Busse, R., “Überblick Über Maßnahmen Zur Förderung Des Einsatzes von Biosimilars in Europäischen Ländern,” Arzneiverordnungs-Report (2022): 57–81.Google Scholar

Dalen, D.M., Strøm, S., and Locatelli, M., “Biosimilar Bidding in Centralized Tenders in Norway,” Nordic Journal of Health Economics 9, no. 1 (2021): 11–23.Google Scholar

Vogler, S., Schneider, P., Zuba, M., Busse, R., and Panteli, D., “Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure,” Frontiers in Pharmacology 12 (2021): 1479.CrossRefGoogle ScholarPubMed

“New International Record for Switch to Biosimilar,” n.d., Amgros, available at <https://amgros.dk/en/knowledge-and-analyses/articles/new-international-record-for-switch-to-biosimilar/?report=reader> (last visited July 28, 2023); T.B. Jensen, S.C. Kim, E. Jimenez-Solem, D. Bartels, H. Rolighed Christensen, and J. Trærup Andersen, “Shift from Adalimumab Originator to Biosimilars in Denmark.” JAMA Internal Medicine 180, no. 6 (2020): 902-903.+(last+visited+July+28,+2023);+T.B.+Jensen,+S.C.+Kim,+E.+Jimenez-Solem,+D.+Bartels,+H.+Rolighed+Christensen,+and+J.+Trærup+Andersen,+“Shift+from+Adalimumab+Originator+to+Biosimilars+in+Denmark.”+JAMA+Internal+Medicine+180,+no.+6+(2020):+902-903.>Google Scholar

T. Bossert, N. Blanchet, S. Sheetz, D.M. Pinto, J. Cali, and R. Pérez-Cuevas, “Comparative Review of Health System Integration in Selected Countries in Latin America,” 2014, available at <https://www.semanticscholar.org/paper/Comparative-Review-of-Health-System-Integration-in-Bossert-Blanchet/d4293e5e720da2802b628a9e60e2af65f5928819> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

Id. Google Scholar

Justo, N., Espinoza, M.A., Ratto, B., Nicholson, M., Rosselli, D., Ovcinnikova, O., García Martí, S., Ferraz, M.B., Langsam, M., and Drummond, M.F., “Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies from Latin America,” Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 22, no. 6 (2019): 739–749; A. Pichon-Riviere, F. Augustovski, S.García Martí, V. Alfie, and L. Sampietro-Colom, “The Link between Health Technology Assessment and Decision Making for the Allocation of Health Resources in Latin America,” International Journal of Technology Assessment in Health Care 36, no. 2 (2020): 173-178.CrossRefGoogle ScholarPubMed

Emmerick, I.C. Martins, Luiza, V.L., Camacho, L.A. Bastos, Vialle-Valentin, C., and Ross-Degnan, D., “Barriers in Household Access to Medicines for Chronic Conditions in Three Latin American Countries,” International Journal for Equity in Health 14, no. 1 (2015).Google ScholarPubMed

Espin Balbino, et al., supra note 12; Tobar and Martich, supra note 5.Google Scholar

WHO Guideline, supra note 7.Google Scholar

Azevedo, V.F., Babini, A., Caballero-Uribe, C.V., Castañeda-Hernández, G., Borlenghi, C., and Jones, H.E., “Practical Guidance on Biosimilars, with a Focus on Latin America: What Do Rheumatologists Need to Know?” Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases 25, no. 2 (2019): 91–100.Google ScholarPubMed

PAHO Revolving Fund, n.d., Pan American Health Organization, available at <https://www.paho.org/en/revolving-fund> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

SE-COMISCA: Consejo de Ministros de Salud de Centroamérica y República Dominicana, n.d., available at <https://comisca.net/> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

EUnetHTA, n.d., available at <https://www.eunethta.eu/> (last visited July 28, 2023).+(last+visited+July+28,+2023).>Google Scholar

Vogler, et al., supra note 49.Google Scholar